Identification of New Differentially Methylated Genes That Have Potential Functional Consequences in Prostate Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Kim, Jin W ^a   Kim, Seong Tae ^a   Turner, Aubrey R ^a   Young, Tracey ^a   Smith, Shelly ^a   Liu, Wennuan ^a   Lindberg, Johan ^b   Egevad, Lars ^b   Gronberg, Henrik ^b   Isaacs, William B ^c   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE P1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TUMOR MARKER;

ANALYTICAL PARAMETERS; AOX1 GENE; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER DIAGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DIFFERENTIALLY METHYLATED CPG SITE; DISEASE ASSOCIATION; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GLEASON SCORE; GSTP1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PILOT STUDY; PPARGC1A GENE; PREDICTIVE VALUE; PROMOTER REGION; PROSTATE CANCER; SENSITIVITY ANALYSIS; SPON2 GENE; UPREGULATION; VALIDATION PROCESS;

ALDEHYDE OXIDASE; CPG ISLANDS; DNA METHYLATION; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84868312894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048455     Document Type: Article

References (55)

1. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, et al. (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462: 315-322.
2. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, et al. (2010) Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466: 253-257.
3. Esteller M, (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440.
4. Herman JG, Baylin SB, (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
5. Deaton AM, Bird A, (2011) CpG islands and the regulation of transcription. Genes Dev 25: 1010-1022.
6. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91: 9700-9704.
7. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692.
8. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, et al. (2001) Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752.
9. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, et al. (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299: 1753-1755.
10. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, et al. (2008) PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36: D842-D846.
11. Suzuki MM, Bird A, (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476.
12. Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, et al. (2010) Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 28: 1106-1114.
13. Harris RA, Wang T, Coarfa C, Nagarajan RP, Hong C, et al. (2010) Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol 28: 1097-1105.
14. Laird PW, (2010) Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 11: 191-203.
15. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, et al. (2009) Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 4: e4830.
16. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, et al. (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21: 1028-1041.
17. Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, et al. (2011) Genome-wide methylation analysis identifies involvement of TNF-alpha mediated cancer pathways in prostate cancer. Cancer Lett 302: 47-53.
18. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, et al. (2011) DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21: 1017-1027.
19. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, et al. (2012) Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 72: 616-625.
20. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, et al. (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18: 2882-2895.
21. Ushijima T, (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231.
22. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, et al. (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6: 692-702.
23. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, et al. (2011) High density DNA methylation array with single CpG site resolution. Genomics 98: 288-295.
24. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869-3873.
25. Kim JW, Cheng Y, Liu W, Li T, Yegnasubramanian S, et al. (2009) Genetic and epigenetic inactivation of LPL gene in human prostate cancer. Int J Cancer 124: 734-738.
26. Shen L, Guo Y, Chen X, Ahmed S, Issa JP (2007) Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques 42: 48, 50, 52.
27. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 1: 177-200.
28. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, et al. (2005) BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 21: 4067-4068.
29. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
30. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548.
31. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, et al. (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11: 587.
32. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, et al. (2009) Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 5: e1000602.
33. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, et al. (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271-282.
34. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, et al. (2005) Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129: 1454-1463.
35. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, et al. (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53: 8441-8460.
36. Shaw S, Jayatilleke E, (1990) The role of aldehyde oxidase in ethanol-induced hepatic lipid peroxidation in the rat. Biochem J 268: 579-583.
37. Sigruener A, Buechler C, Orso E, Hartmann A, Wild PJ, et al. (2007) Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Horm Metab Res 39: 781-789.
38. Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, et al. (2011) Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 129: 2855-2866.
39. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, et al. (2010) Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16: 21-33.
40. Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat MA, et al. (2011) Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 30: 151-161.
41. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
42. Kanehisa M, Goto S, (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
43. Feinstein Y, Borrell V, Garcia C, Burstyn-Cohen T, Tzarfaty V, et al. (1999) F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons. Development 126: 3637-3648.
44. He YW, Li H, Zhang J, Hsu CL, Lin E, et al. (2004) The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat Immunol 5: 88-97.
45. Romanuik TL, Ueda T, Le N, Haile S, Yong TM, et al. (2009) Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol 175: 2264-2276.
46. Parry R, Schneider D, Hudson D, Parkes D, Xuan JA, et al. (2005) Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res 65: 8397-8405.
47. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P, (2008) Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 582: 46-53.
48. Handschin C, Spiegelman BM, (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735.
49. Tcherepanova I, Puigserver P, Norris JD, Spiegelman BM, McDonnell DP, (2000) Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. J Biol Chem 275: 16302-16308.
50. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, et al. (2010) Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol 24: 114-127.
51. Wirtenberger M, Tchatchou S, Hemminki K, Schmutzhard J, Sutter C, et al. (2006) Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis 27: 2201-2208.
52. Malumbres M, Perez dC, I, Santos J, Fernandez PJ, Pellicer A, (1999) Hypermethylation of the cell cycle inhibitor p15INK4b 3′-untranslated region interferes with its transcriptional regulation in primary lymphomas. Oncogene 18: 385-396.
53. Deaton AM, Webb S, Kerr AR, Illingworth RS, Guy J, et al. (2011) Cell type-specific DNA methylation at intragenic CpG islands in the immune system. Genome Res 21: 1074-1086.
54. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP, (2009) A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci U S A 106: 671-678.
55. Shenker N, Flanagan JM, (2012) Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer 106: 248-253.